Please ensure Javascript is enabled for purposes of website accessibility

Why Boingo Wireless, DaVita, and Constellation Pharmaceuticals Jumped Today

By Dan Caplinger - Nov 6, 2019 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks rose in a quiet market.

Stocks finished Wednesday's session close to where they started, with major market benchmarks getting pushed and pulled by conflicting readings on the health of the U.S. economy and the 10-year-old bull market. Investors seem to be waiting for some positive catalyst to send indexes further into record territory, but some individual stocks saw nice moves higher on upbeat news. Boingo Wireless (WIFI), DaVita (DVA -0.89%), and Constellation Pharmaceuticals (CNST) were among the top performers. Here's why they did so well.

Boingo gets a nice win

Shares of Boingo Wireless soared nearly 30% after the company reported its third-quarter financial results. Revenue eased lower by 1% compared to the year-earlier period, and the wireless provider still lost money, albeit less than it did 12 months ago. Yet investors were pleased to hear that Boingo extended a contract with the Army and Air Force Exchange Service for another 15 years through 2038, providing the service to more than 350,000 members of the military on 64 different bases. With greater demand for wireless availability in a wide range of public spaces, Boingo has a great opportunity to keep moving higher after going through tough times recently.

Animated people on top of wireless network symbols.

Image source: Getty Images.

DaVita looks healthy

DaVita saw its stock pick up 13% following its release of its third-quarter financial report. Revenue inched higher by 2% compared to year-earlier levels, but the company reversed a loss in the prior-year period, and adjusted net income more than doubled year over year. Helping DaVita's bottom line was a considerable drop in operating expenses, and the kidney disease and dialysis specialist boosted its outlook for both this year and next. DaVita has been doing significant share repurchases as well, and between solid earnings and confidence in the stock, investors appear to see a lot more potential from the company.

Constellation heads for the stars

Finally, shares of Constellation Pharmaceuticals skyrocketed 90%. The clinical-stage biopharmaceutical company gave promising data from its phase 2 trial of its CPI-0610 treatment for myelofibrosis, and Constellation decided to expand the study in order to get a better handle on just how important the drug might be for a broader range of disease sufferers. Even after today's move higher, Constellation's market cap weighs in at just $700 million. If CPI-0610 or other drugs in its pipeline prove to have blockbuster potential, then today's gains could be just the start for Constellation shareholders.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DaVita Inc. Stock Quote
DaVita Inc.
$93.41 (-0.89%) $0.84
Boingo Wireless, Inc. Stock Quote
Boingo Wireless, Inc.
Constellation Pharmaceuticals, Inc. Stock Quote
Constellation Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.